Organization
University of Valencia
1 clinical trial
6 abstracts
Abstract
Effect of ctDNA whole-exome sequencing in pancreatic adenocarcinoma on prognostic value, actionable alterations, and organ tropisms in metastatic disease.Org: University of Valencia, Instituto Carlos III,
Clinical trial
Impact of the Type of Treatment of the Endometrioma on Ovarian ReserveStatus: Recruiting, Estimated PCD: 2024-11-02
Abstract
First-in-human dose-escalation trial of BI 764532, a delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager in patients (pts) with DLL3-positive (DLL3+) small-cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC).Org: Technical University Dresden, Medical Faculty, NCT/UCC Early Clinical Trial Unit, NCT/UCC Early Clinical Trial Unit, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Institute of Oncology,
Abstract
The CIRCULATE Spain study: Circulating tumor DNA based decision for adjuvant treatment in localized colon cancer.Org: INCLIVA Biomedical Research Institute, University of Valencia, Instituto Carlos III, CIBERONC, Biostatistics Unit,
Abstract
Investigating the novel CD16A and epidermal growth factor receptor (EGFR) bispecific innate cell engager, AFM24, to leverage the innate immune system: Interim results from the colorectal cancer (CRC) cohort.Org: INCLIVA-Biomedical Research Institute, Biomedical Research Institute INCLIVA, Hospital Clínico Universitario-INCLIVIA, Valencia, Spain, University of Valencia, Affimed Inc.,
Abstract
The combination of APR-246 and carboplatin in olaparib-resistant high grade serous ovarian cancer (HGSOC) and triple negative breast cancer (TNBC) cell lines.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Hospital Clínico Universitario de Valencia, Instituto de Investigación Sanitaria (INCLIVA), Translational Oncology and Pathology Group, La Paz University Hospital-IdiPAZ,
Abstract
Phase 2 study of elraglusib (9-ING-41), a glycogen synthase kinase-3b inhibitor, in combination with gemcitabine plus nab-paclitaxel (GnP) in patients with previously untreated advanced pancreatic ductal adenocarcinoma (PDAC).Org: Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Robert H Lurie Comprehensive Cancer Center, Chicago, IL, University of Pittsburgh Medical Center (UPMC), Department of Medicine, Icahn School of Medicine at Mount Sinai,